Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Investing.com - Eli Lilly's (NYSE: LLY) full-year profit forecast largely surpassed Wall Street expectations on Thursday, as ...

Asthma-Allergy Denmark has detected pollen from alder trees and hazel bushes in its monitoring stations, officially kicking off the 2025 pollen season. This marks the beginning of allergy symptoms ...

Investing.com - Eli Lilly's full-year profit forecast largely surpassed Wall Street expectations on Thursday, as the ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Yesterday, four of Denmark’s largest companies released their financial reports: Demant, Lundbeck, Pandora, and Vestas. All of them are part of the C25 index, which includes the country’s largest ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk (NVO), the maker of the popular GLP-1 medications Wegovy and Ozempic, said potential tariffs on Europe imposed ...

The Danish pharmaceutical company expects demand for obesity and diabetes drugs to rise, but forecasts sales growth to slow down this year. Read more.